A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
about
Recent advances in the development of vaccines for tuberculosisPrime-boost approaches to tuberculosis vaccine developmentNovel viral vectored vaccines for the prevention of influenza.The duration of antigen-stimulation significantly alters the diversity of multifunctional CD4 T cells measured by intracellular cytokine stainingComparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal deliveryThe next 10 years for tuberculosis vaccines: do we have the right plans in place?Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell responseSafety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice.Vaccine against tuberculosis: what's new?Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety ConsiderationsSafety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG.Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A.The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.Aerosol immunisation for TB: matching route of vaccination to route of infectionA review of clinical models for the evaluation of human TB vaccines.Global Efforts in the Development of Vaccines for Tuberculosis: Requirements for Improved Vaccines Against Mycobacterium tuberculosis.From AIDS to TB vaccines--A career in infectious diseases and translational vaccinology.How Can Elispot Add Information to Improve Knowledge on Tropical Diseases?Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin (BCG) for Infants of HIV Infected Mothers: A Phase 2 Randomized Controlled Trial.Recent developments in tuberculosis vaccines
P2860
Q26796440-FF273D58-5F83-4478-815A-5BDF61BA4197Q27024526-4A3035EF-1C0A-4D29-A1BB-A650125B1FBBQ30418570-AE685DDB-9C68-467E-B499-587FBD05FBCFQ31068532-E87FE79C-733F-43B9-B636-C724D2C56D58Q33603206-F789078A-20FA-4ACE-8968-727FE538BA8EQ33659150-EACAB5D1-8A08-4CCD-864D-2DD801F52ACEQ33770851-92B9D6A8-6546-4217-9844-173AC730B697Q34663035-AABC0E5A-46AE-47C5-A0D5-D708ECDDF10AQ34806664-4EFBE9BF-0AE0-4133-B3B9-412673A76935Q35032532-B5802B47-479F-4819-871D-E4049DD0B795Q35101472-A64E50B4-3CFF-4AF2-B326-51D535D1C52DQ35826779-E93B2863-FA28-4213-8CE7-E3A354479F8BQ36287555-B5A6DA08-41CB-4082-84D4-B96CC99FF470Q36715923-392A184C-FCF2-4DFD-93C3-1DE6A3732E6CQ36888036-A4B9EA13-60C6-4FB5-87F0-68DCDDAC53CFQ36980878-1265671D-7B81-48B9-A7F0-6EDE6988C7C7Q37548692-FA73AB48-7739-4046-9C7A-EEA3D8592A4AQ38338183-292AADD7-FD38-44D2-97B7-486E0B446693Q38711772-525F15A2-F497-4F0B-8870-A0E7B6CF04CDQ38907507-0A67AB51-581F-4B33-BDB4-365A4E46303EQ40914004-F95C31C0-7295-4DCC-A478-ED302B1FC697Q41928044-C083F0B4-5DD9-4380-8E84-969B8E4B5DC7Q47613899-1582D97C-3945-4353-9CB1-48A70B427886Q58834925-88789420-6210-49C3-A3E1-FC017BA80A36
P2860
A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A Phase I study evaluating the ...... accine, in HIV-infected adults
@ast
A Phase I study evaluating the ...... accine, in HIV-infected adults
@en
A Phase I study evaluating the ...... accine, in HIV-infected adults
@nl
type
label
A Phase I study evaluating the ...... accine, in HIV-infected adults
@ast
A Phase I study evaluating the ...... accine, in HIV-infected adults
@en
A Phase I study evaluating the ...... accine, in HIV-infected adults
@nl
prefLabel
A Phase I study evaluating the ...... accine, in HIV-infected adults
@ast
A Phase I study evaluating the ...... accine, in HIV-infected adults
@en
A Phase I study evaluating the ...... accine, in HIV-infected adults
@nl
P2093
P2860
P50
P1433
P1476
A Phase I study evaluating the ...... accine, in HIV-infected adults
@en
P2093
Alan Winston
Alison M Lawrie
Ansar A Pathan
Brenna J Hill
Clare R Sander
Daniel C Douek
David A Price
David R Ambrozak
Guy Rooney
Hazel Poyntz
P2860
P304
P356
10.1136/BMJOPEN-2011-000223
P407
P577
2011-11-14T00:00:00Z